U.S. Markets open in 7 hrs 47 mins
  • S&P Futures

    4,279.00
    -62.50 (-1.44%)
     
  • Dow Futures

    33,640.00
    -415.00 (-1.22%)
     
  • Nasdaq Futures

    13,907.75
    -250.75 (-1.77%)
     
  • Russell 2000 Futures

    1,935.10
    -37.60 (-1.91%)
     
  • Crude Oil

    86.61
    -0.74 (-0.85%)
     
  • Gold

    1,810.40
    -19.30 (-1.05%)
     
  • Silver

    23.23
    -0.58 (-2.44%)
     
  • EUR/USD

    1.1226
    -0.0019 (-0.1684%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3425
    -0.0037 (-0.2779%)
     
  • USD/JPY

    114.6900
    +0.0300 (+0.0262%)
     
  • BTC-USD

    36,075.00
    -1,367.11 (-3.65%)
     
  • CMC Crypto 200

    820.92
    -34.89 (-4.08%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,170.30
    -841.00 (-3.11%)
     

Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • FLGT

TEMPLE CITY, Calif., November 09, 2021--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics" or the "company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to virtually participate in the following investor conferences:

Credit Suisse 30th Annual Healthcare Conference
Wednesday, November 10, 2021
Live presentation at 4:20 p.m. Eastern Time (1:20 p.m. Pacific Time)

Piper Jaffray 33rd Annual Healthcare Conference
Wednesday, December 1, 2021

Webcasts of the presentations will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com.

About Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing ("NGS") with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005721/en/

Contacts

Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com